10-K: BioLargo Reports Increased Revenue but Continues to Face Going Concern Challenges in 2024 10-K Filing

BioLargo's 2024 10-K filing reveals a 45% revenue increase driven by private-label odor control products, but the company still faces net losses and going concern uncertainties.

Summary

• BioLargo's 10-K filing for the year ended December 31, 2024, indicates a 45% increase in revenue, reaching $17.779 million, compared to 2023.
• The revenue growth was primarily driven by a 46% increase in product sales, particularly private-label odor control products like Pooph.
• Despite the revenue increase, the company reported a net loss of $4.347 million for 2024, a slight improvement from the $4.648 million loss in 2023.
• The company's auditor included an explanatory paragraph in their opinion, raising substantial doubt about BioLargo's ability to continue as a going concern due to recurring losses from operations.
• BioLargo relies on sales of its securities, including sales to Lincoln Park Capital Fund, to bridge the gap between operational revenue and expenses.
• The company's wholly-owned subsidiary, ONM Environmental, saw a 36% increase in revenue, primarily due to the success of the Pooph branded pet odor product.
• BioLargo Engineering, Science & Technologies (BLEST) experienced a 183% increase in third-party revenue, driven by sales of AEC water treatment equipment.
• Clyra Medical Technologies, Inc. is still in the development phase and has not yet begun commercial sales of its Bioclynse surgical wound irrigation product.
• BioLargo Energy Technologies, Inc. (BETI) is focused on developing its Cellinity battery technology and has not yet generated revenue.
• BioLargo Equipment, Sciences and Technologies, Inc. (BEST) was formed in 2024 to commercialize BioLargo's proprietary water treatment equipment, including its PFAS removal device the AEC.
• The company has a share purchase agreement with Lincoln Park Capital Fund, LLC, allowing them to sell up to $10 million of common stock, subject to certain limitations.
• BioLargo has 26 patents issued and multiple applications pending, with an average remaining duration of seven years.
• The company acknowledges that its internal controls are not effective and that it needs to invest in additional personnel to better manage the financial reporting processes.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue increased, the company continues to face significant financial challenges, including net losses and going concern uncertainties. The reliance on stock sales to fund operations is also a concern.

Positives

• Revenue increased by 45% to $17.779 million in 2024.
• ONM Environmental's revenue increased by 36%, driven by the success of the Pooph branded pet odor product.
• BLEST's third-party revenue increased by 183%, driven by sales of AEC water treatment equipment.
• The company's net loss for 2024 was $4.347 million, a slight improvement from the $4.648 million loss in 2023.

Negatives

• The company reported a net loss of $4.347 million for 2024.
• The auditor's report includes an explanatory paragraph raising substantial doubt about BioLargo's ability to continue as a going concern.
• BioLargo relies on sales of its securities, including sales to Lincoln Park Capital Fund, to fund its operations.
• The company acknowledges that its internal controls are not effective and that it needs to invest in additional personnel to better manage the financial reporting processes.

Risks

• The company has incurred net losses on an annual basis since its inception and may continue to experience losses and negative cash flow in the future.
• The company's cash requirements are significant, and it will continue to require additional financing to sustain its operations.
• The company's ability to access capital markets could be limited.
• The company's revenue growth rate may slow over time.
• The company does not have contracts with customers that require the purchase of a minimum amount of its products.
• The company may face supply chain challenges, including supply and pricing volatility.
• Tariffs on imported goods may adversely affect prices of the company's raw materials.
• If the company's technology or products incorporating its technology do not gain market acceptance, it is unlikely that the company will become profitable.
• If the company is not able to manage its anticipated growth effectively, it may not become profitable.
• Some of the products incorporating the company's technology will require regulatory approval.
• The company's internal controls are not effective.
• If the company loses its key personnel or is unable to attract and retain additional personnel, it may be unable to achieve profitability.
• The company may become subject to product liability claims.
• Litigation or the actions of regulatory authorities may harm the company's business or otherwise distract its management.
• If the company suffers negative publicity concerning the safety or efficacy of its products, its sales may be harmed.
• The company's revenues and operating results are likely to continue to fluctuate from quarter to quarter.
• The licensing of the company's technology or the manufacture, use or sale of products incorporating its technology may infringe on the patent rights of others, and the company may be forced to litigate if an intellectual property dispute arises.
• The company is subject to risks related to future business outside of the United States.
• The volatility of certain raw material costs may adversely affect operations and competitive price advantages for products that incorporate the company's technology.
• Certain of the company's product sales historically have been highly impacted by fluctuations in seasons and weather.
• There may be battery technologies that the company is not aware of, and some of them may be subject to patent applications.
• The company expects to face strong competition for its products from a growing list of established and new competitors.
• There may not be a market for the company's liquid sodium battery.
• Business disruptions could seriously harm the company's future revenue and financial condition and increase its costs and expenses.
• Increased information technology security threats and more sophisticated computer crime pose a risk to the company and its subsidiaries, vendors, systems, networks, products and services.
• Economic uncertainties and domestic or world events and policies may adversely affect the company's business and operations.
• A recession in the United States may affect the company's business.
• The sale or issuance of the company's common stock to Lincoln Park may cause dilution, and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of the company's common stock to fall.
• The company's common stock is thinly traded and largely illiquid.
• The market price of the company's stock is subject to volatility.
• You may have difficulty selling the company's stock because it is deemed a penny stock and not quoted on a national exchange.
• Because the company's shares are deemed a penny stock, rules enacted by FINRA make it difficult to sell previously restricted stock.
• Because the company will not pay dividends in the foreseeable future, stockholders will only benefit from owning common stock if it appreciates.
• The company regularly issues stock, or stock options, instead of cash, to pay some of its operating expenses.
• The company's stockholders face further potential dilution in any new financing.
• The company's stockholders face further potential adverse effects from the terms of any preferred stock that may be issued in the future.
• The company's business involves the use, transmission and storage of confidential information, and the failure to properly safeguard such information could result in significant reputational harm.

Future Outlook

The company anticipates net losses and negative cash flow to continue for the foreseeable future until its products are expanded in the marketplace and they gain broader acceptance by resellers and customers.

Management Comments

• Management is optimistic that we will succeed in licensing our technology, we cannot be certain as to timing or whether we will generate sufficient revenue to be able to operate profitably.
• Management believes that it can finance commercialization efforts through sales of our securities and possibly other capital sources, if we do not successfully bring our technology to market, our ability to generate revenues will be adversely affected.

Industry Context

BioLargo operates in the cleantech industry, focusing on air quality, water, environmental engineering, battery energy storage, and advanced antimicrobial medical device platforms. The company competes with numerous companies, including larger companies within the hazardous materials line of business such as Clean Earth, Clean Harbors, Republic Services, Veolia and Covanta.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, it mentions competitors like Clean Earth, Clean Harbors, Republic Services, Veolia and Covanta, which are larger companies in the hazardous materials line of business.
• Without specific financial metrics for these competitors, it's difficult to assess BioLargo's performance relative to industry benchmarks.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of stock to fund operations.
• Employees may be impacted by the company's financial challenges and reliance on stock options as compensation.
• Customers may be impacted by the company's ability to continue operations and provide products and services.
• Creditors face increased risk due to the company's financial challenges and reliance on debt financing.

Next Steps

• The company intends to continue to raise investment capital through the sale of its securities and the securities of its subsidiaries.
• The company intends to expand its marketing efforts of its products as financial resources are available, and we intend to continue to expand our research and development efforts.
• The company intends to seek listing on the Nasdaq Stock Market (Nasdaq) or another national stock exchange when our company is eligible.

Key Dates

Keywords

BioLargo, revenue, net loss, going concern, ONM Environmental, BLEST, Clyra Medical, BETI, BEST, Pooph, AEC, PFAS, stock, options, warrants, Lincoln Park, financing, patents, internal controls